Evidence map›Paper›PMID 42321603›Full record

ArticleBMC cardiovascular disorders2026

Qualitative insights into the experiences and goals of people living with severe difficult-to-treat hypertension in Australia.

Michelle Hill, Jenni Godsell

Abstract read
In one paragraph

Article in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Michelle HillMedtronic Australasia, Macquarie Park, NSW, Australia.
Jenni GodsellCommunity and Patient Preference Research Pty Ltd, PO Box 2214, Woolooware, NSW, 2230, Australia. jenni.godsell@cappre.com.au.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOver one-third of Australian adults have hypertension, and this rate increases with age. Difficult-to-treat hypertension is high blood pressure that remains above target levels despite proper medicine adherence. This study explored the treatment experiences and goals of patients with severe difficult-to-treat hypertension to gain insights into renal denervation (RDN) as a therapeutic option.

methodsTwelve Australian participants with severe difficult-to-treat hypertension were interviewed. Participants were recruited via a specialist recruitment company and specialist referral. Semi-structured interviews lasted about 60 min either online or by phone. Interviews were recorded and transcribed verbatim. Transcripts were analyzed using inductive and deductive thematic analysis in NVivo.

resultsParticipants had an average age of 65 years (range: 48-75 years), 58% identified as male and all lived across Australia, primarily in metropolitan areas (n = 9; 75%). The average time since hypertension diagnosis was 22 years (range: 3-44 years) and nearly all participants had a family history of hypertension. Data analysis identified four themes regarding participants' experiences of living with severe difficult-to-treat hypertension and awareness of renal denervation therapy: (1) Diagnosis and monitoring of hypertension, (2) The impact of severe difficult-to-treat hypertension on quality of life, (3) The management of severe difficult-to-treat hypertension and (4) Awareness, perceptions and experiences with RDN.

conclusionsThis study provides an in-depth understanding of the experiences of people living with severe difficult-to-treat hypertension and their treatment goals. It highlights the significant impact and stigma of living with severe difficult-to-treat hypertension, and the need to incorporate psychosocial support and patient education into the clinical management of this chronic condition.

Indexed as

Antihypertensive AgentsBlood PressureGoalsHealth Knowledge, Attitudes, PracticeHypertensionKidneyRenal ArterySympathectomyAgedAustraliaFemaleHumansInterviews as TopicMaleMedication AdherenceMiddle AgedAntihypertensive AgentsBlood pressureInterviewPatient participationQualitative researchRenal denervationSevere difficult-to-treat hypertension

Identifiers

PMID42321603
PMCPMC13523477

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.